Table 5.

Clinical/treatment alterations guided by biopsy results.

Was there a major clinical/treatment alteration due to bone biopsy? (Removing Parathyroidectomy Candidacy), n (%)	66
No	9 (13.6)
Yes	49 (74.2)
Keep Treatment Course	7 (10.6)
Unknown (No Follow Up)	1 (1.5)
Those with No, why? n (%)	9
Patient Status Declined	5 (55.5)
Normal Bone Histology	1 (11.1)
Teriparatide already used for 2 years, romosozumab not studied in transplant patients	1 (11.1)
Teriparatide recommended, but patient history of metastatic breast cancer and prior radiation treatment and therefore unknown risks	1 (11.1)
Patient did not want medication/treatment offered	1 (11.1)
Those with Yes or Keep Treatment Course (55), Did treatment align with histology recommendation? n (%)	55
No	6 (10.9)
Yes	45 (81.8)
Anabolic therapy recommended, patient already completed 2 years of teriparatide treatment, IV zoledronic acid started instead	1 (1.8)
Antiresorptive therapy recommended, patient was already started on teriparatide, and patient was fracturing on actonel therefore teriparatide treatment kept	1 (1.8)
Anabolic therapy recommended, teriparatide only option at the time but patient did not want daily injections, therefore IV pamidronate started for 2 years with no improvement, patient eventually started and completed 2 years of teriparatide	1 (1.8)
No Treatment, but further diagnostics	2 (3.6)
Was there a major treatment alteration due to bone biopsy? (Including Parathyroidectomy Candidacy), n (%)	95
No	10 (10.5)
Yes	70 (73.7)
Keep Treatment Course	7 (7.4)
Unknown (No Follow Up)	8 (8.4)
Those with No, why? n (%)	10
Patient Status Decline	6 (60)
Normal Bone Histology	1 (10)
Teriparatide already used for 2 years, romosozumab not studied in transplant patients	1 (10)
Teriparatide recommended, but patient history of metastatic breast cancer and prior radiation treatment and therefore unknown risks	1 (10)
Patient did not want medication/treatment offered	1 (10)
Those with Yes or Keep Treatment Course (76), Did treatment align with histology recommendation? n (%)	76
No	6 (7.9)
Yes	66 (86.8)
Anabolic therapy recommended, patient already completed 2 years of teriparatide treatment, IV zoledronic acid started instead	1 (1.3)
Antiresorptive therapy recommended, patient was already started on teriparatide, and patient was fracturing on actonel, therefore teriparatide treatment kept	1 (1.3)
Anabolic therapy recommended, teriparatide only option at the time but patient did not want daily injections, therefore IV pamidronate started for 2 years with no improvement, patient eventually completed 2 years of teriparatide	1 (1.3)
No Treatment, but further diagnostics	2 (2.6)